Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide - PubMed (original) (raw)
doi: 10.1038/sj.clpt.6100409. Epub 2007 Oct 31.
S M Greiner, M E Harvey, G Griesmann, M J Kuffel, S A Buhrow, J M Reid, M Federspiel, M M Ames, D Dingli, K Schweikart, A Welch, A Dispenzieri, K-W Peng, S J Russell
Affiliations
- PMID: 17971816
- PMCID: PMC2769566
- DOI: 10.1038/sj.clpt.6100409
Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide
R M Myers et al. Clin Pharmacol Ther. 2007 Dec.
Abstract
MV-NIS is an oncolytic measles virus encoding the human thyroidal sodium iodide symporter (NIS). Here, we report the results of preclinical pharmacology and toxicology studies conducted in support of our clinical protocol "Phase I Trial of Systemic Administration of Edmonston Strain of Measles Virus, Genetically Engineered to Express NIS, with or without Cyclophosphamide, in Patients with Recurrent or Refractory Multiple Myeloma." Dose-response studies in the KAS-6/1 myeloma xenograft model demonstrated a minimum effective dose of 4 x 10(6) TCID50 (tissue culture infectious dose 50)/kg. Toxicity studies in measles-naive squirrel monkeys and measles-susceptible transgenic mice were negative at intravenous doses up to 10(8) and 4 x 10(8) TCID50/kg, respectively. Abundant viral mRNA, maximal on day 8, was detected in cheek swabs of squirrel monkeys, more so after pretreatment with cyclophosphamide. On the basis of these data, the safe starting dose of MV-NIS for our clinical protocol was set at 1-2 x 10(4) TCID50/kg (10(6) TCID50 per patient).
Conflict of interest statement
CONFLICT OF INTEREST
The authors declared no conflict of interest.
Figures
Figure 1
Schematic illustration of the derivation of the infectious molecular clone (MV-Tag) that was used to generate recombinant MV-NIS by reverse genetics. The numbers indicate the number of passages in each of the indicated cellular substrate. (Adapted from ref. 2.)
Figure 2
Schematic representations of the MVs rescued from the plasmid molecular clones used to derive MV-NIS: p(+)MV-tag produced MVtag; p(+)MHlrGFPV produced MHlrGFPV; and p(+)MH-NIS(HP)3 produced the drug substance MV-NIS. To construct p(+)MH-NIS(HP)3, the _Mlu_I–_Aat_II fragment of p(+)MHlrGFPV containing the additional gene encoding rGFP was replaced with a PCR product containing the human NIS gene flanked by _Mlu_I and _Aat_II sites. An artificial gene boundary region (nucleotide sequence shown) was inserted into the _Spe_I site (position 9234) using two synthesized oligonucleotides. The p(+)MHlrGFPV plasmid was constructed by inserting the rGFP coding region into the _Mlu_I and _Nru_I cloning sites of the polylinker. The _Aat_II site is in the rGFP 3′-non-coding sequence. The p(+)MH-NIS(HP)3 plasmid was constructed by inserting the human NIS coding region into the _Mlu_I and _Aat_II sites of p(+)MHlrGFPV, replacing the rGFP gene. The position of the gene coding regions is indicated above the MVtag genome. To facilitate the comparison of the MV-NIS genome sequence (17,940 nucleotides) with other MV genomes of the Edmonston lineage (15,894 nucleotides), the 2,046 bp inserted transcription unit containing the NIS coding region is numbered separately (1N–2046N).
Figure 3
Schema for phase I clinical trial to assess the safety, maximum tolerated dose, and preliminary efficacy of MV-NIS administered intravenously with and without cyclophosphamide in patients with relapsed or refractory multiple myeloma. Correlative studies performed are summarized in the table of this figure.
Figure 4
Survival and individual tumor volume in SCID mice bearing subcutaneous KAS-6/1 multiple myeloma xenografts treated with various doses of MV-NIS. (a) Survival proportions (UV-inactivated, black; 104 TCID50, red; 105 TCID50, blue; 106 TCID50, green; 107 TCID50, purple). Individual tumor volumes plotted for mice treated with (b) UV-inactivated, (c) 104 TCID50, (d) 105 TCID50, (e) 106 TCID50, and (f) 107 TCID50 MV-NIS.
Figure 5
Biodistribution of MV-NIS genome in IfnarKO × CD46 Ge mice after intravenous administration of 107 TCID50 MV-NIS day 0 with and without 125 mg/kg cyclophosphamide (CP) pretreatment day −1. (a) Day 2, (b) day 5, (c) day 22, (d) day 91. Data normalized per microgram of total RNA. Closed diamonds, without CP; open diamonds, with CP; black, brain; red, lung; blue, liver; orange, kidney; green, spleen; purple, blood; and brown, gonads. Limit of detection (LOD) of QRT-PCR assay is 100 copies of MV nucleoprotein RNA per microgram of total RNA.
Similar articles
- Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma.
Dispenzieri A, Tong C, LaPlant B, Lacy MQ, Laumann K, Dingli D, Zhou Y, Federspiel MJ, Gertz MA, Hayman S, Buadi F, O'Connor M, Lowe VJ, Peng KW, Russell SJ. Dispenzieri A, et al. Leukemia. 2017 Dec;31(12):2791-2798. doi: 10.1038/leu.2017.120. Epub 2017 Apr 25. Leukemia. 2017. PMID: 28439108 Free PMC article. Clinical Trial. - Oncolytic measles virus encoding thyroidal sodium iodide symporter for squamous cell cancer of the head and neck radiovirotherapy.
Li H, Peng KW, Russell SJ. Li H, et al. Hum Gene Ther. 2012 Mar;23(3):295-301. doi: 10.1089/hum.2011.128. Epub 2012 Jan 11. Hum Gene Ther. 2012. PMID: 22235810 Free PMC article. - Safety Study: Intraventricular Injection of a Modified Oncolytic Measles Virus into Measles-Immune, hCD46-Transgenic, IFNαRko Mice.
Lal S, Peng KW, Steele MB, Jenks N, Ma H, Kohanbash G, Phillips JJ, Raffel C. Lal S, et al. Hum Gene Ther Clin Dev. 2016 Dec;27(4):145-151. doi: 10.1089/humc.2016.062. Epub 2016 Sep 7. Hum Gene Ther Clin Dev. 2016. PMID: 27604429 - Clinical testing of engineered oncolytic measles virus strains in the treatment of cancer: an overview.
Msaouel P, Dispenzieri A, Galanis E. Msaouel P, et al. Curr Opin Mol Ther. 2009 Feb;11(1):43-53. Curr Opin Mol Ther. 2009. PMID: 19169959 Free PMC article. Review. - Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects.
Msaouel P, Opyrchal M, Dispenzieri A, Peng KW, Federspiel MJ, Russell SJ, Galanis E. Msaouel P, et al. Curr Cancer Drug Targets. 2018;18(2):177-187. doi: 10.2174/1568009617666170222125035. Curr Cancer Drug Targets. 2018. PMID: 28228086 Free PMC article. Review.
Cited by
- Triple-Negative Breast Cancer: Basic Biology and Immuno-Oncolytic Viruses.
Monaco ML, Idris OA, Essani K. Monaco ML, et al. Cancers (Basel). 2023 Apr 21;15(8):2393. doi: 10.3390/cancers15082393. Cancers (Basel). 2023. PMID: 37190321 Free PMC article. Review. - HDAd6/35++ - A new helper-dependent adenovirus vector platform for in vivo transduction of hematopoietic stem cells.
Wang H, Georgakopoulou A, Zhang W, Kim J, Gil S, Ehrhardt A, Lieber A. Wang H, et al. Mol Ther Methods Clin Dev. 2023 Mar 21;29:213-226. doi: 10.1016/j.omtm.2023.03.008. eCollection 2023 Jun 8. Mol Ther Methods Clin Dev. 2023. PMID: 37081854 Free PMC article. - Oncolytic Urabe mumps virus: A promising virotherapy for triple-negative breast cancer.
Behrens MD, Stiles RJ, Pike GM, Sikkink LA, Zhuang Y, Yu J, Wang L, Boughey JC, Goetz MP, Federspiel MJ. Behrens MD, et al. Mol Ther Oncolytics. 2022 Nov 14;27:239-255. doi: 10.1016/j.omto.2022.11.002. eCollection 2022 Dec 15. Mol Ther Oncolytics. 2022. PMID: 36458203 Free PMC article. - Preclinical safety assessment of MV-s-NAP, a novel oncolytic measles virus strain armed with an H . pylori immunostimulatory bacterial transgene.
Viker KB, Steele MB, Iankov ID, Concilio SC, Ammayappan A, Bolon B, Jenks NJ, Goetz MP, Panagioti E, Federspiel MJ, Liu MC, Peng KW, Galanis E. Viker KB, et al. Mol Ther Methods Clin Dev. 2022 Jul 31;26:532-546. doi: 10.1016/j.omtm.2022.07.014. eCollection 2022 Sep 8. Mol Ther Methods Clin Dev. 2022. PMID: 36092362 Free PMC article. - Infection of non-cancer cells: A barrier or support for oncolytic virotherapy?
Naumenko VA, Stepanenko AA, Lipatova AV, Vishnevskiy DA, Chekhonin VP. Naumenko VA, et al. Mol Ther Oncolytics. 2022 Feb 12;24:663-682. doi: 10.1016/j.omto.2022.02.004. eCollection 2022 Mar 17. Mol Ther Oncolytics. 2022. PMID: 35284629 Free PMC article. Review.
References
- Enders JF, Peebles TC. Propagation in tissue cultures of cytopathogenic agents from patients with measles. Proc Soc Exp Biol Med. 1954;86:277–286. - PubMed
- Rota JS, Wang ZD, Rota PA, Bellini WJ. Comparison of sequences of the H, F, and N coding genes of measles virus vaccine strains. Virus Res. 1994;31:317–330. - PubMed
- Nakamura T, Russell SJ. Oncolytic measles viruses for cancer therapy. Expert Opin Biol Ther. 2004;4:1685–1692. - PubMed
- Peng KW, et al. Systemic therapy of myeloma xenografts by an attenuated measles virus. Blood. 2001;98:2002–2007. - PubMed
- Peng KW, et al. Intraperitoneal therapy of ovarian cancer using an engineered measles virus. Cancer Res. 2002;62:4656–4662. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R01 CA100634-04/CA/NCI NIH HHS/United States
- R01 CA118488-03/CA/NCI NIH HHS/United States
- CA100634/CA/NCI NIH HHS/United States
- CA118488/CA/NCI NIH HHS/United States
- R01 CA100634/CA/NCI NIH HHS/United States
- R01 CA118488/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical